Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jan 19;9(1):6-11.
doi: 10.1159/000454876. eCollection 2017 Jan-Apr.

Azathioprine Hypersensitivity Syndrome: Two Cases of Febrile Neutrophilic Dermatosis Induced by Azathioprine

Affiliations
Case Reports

Azathioprine Hypersensitivity Syndrome: Two Cases of Febrile Neutrophilic Dermatosis Induced by Azathioprine

Majed Aleissa et al. Case Rep Dermatol. .

Abstract

Background: Azathioprine is an immunosuppressive agent used in the treatment of immune-mediated diseases. Azathioprine hypersensitivity syndrome is a rare adverse reaction occurring a few days to weeks after the administration of azathioprine.

Case 1: A 36-year-old male with ulcerative colitis presented with erythematous plaques, pustules and erosions on the lower back, buttocks and thighs associated with high fever (39°C) 2 weeks after the initiation of azathioprine 100 mg/day. Additional findings included leukocytosis (18.6 g/L) with neutrophilia (11.1 g/L) and elevated C-reactive protein (128 mg/L). Histopathology showed a dense infiltrate of neutrophils in the hair follicles. We increased the dose of prednisone to 1 mg/kg/day (60 mg/day) and azathioprine was discontinued. He had marked improvement within 3 weeks and did not have any relapse with a 1-year follow-up.

Case 2: A 57-year-old male with ulcerative colitis presented with erythematous plaques and pustules on the lower limbs associated with high fever (40°C) 1 week after the initiation of azathioprine 75 mg/day. Leukocytosis with neutrophilia (13.6 g/L) and elevated C-reactive protein (344 mg/L) were among the laboratory findings. Histopathology showed a dense infiltrate of neutrophils in the hair follicles. The dose of prednisone was increased to 20 mg/day and azathioprine was discontinued, which led to complete remission within 7 days. He did not have any relapse with a 6-month follow-up.

Conclusion: The development of acute neutrophilic dermatitis 2 weeks after the initiation of azathioprine and the complete resolution after its withdrawal were in favor of azathioprine hypersensitivity syndrome. It should not be confused with Sweet syndrome associated with inflammatory bowel disease, as maintenance of azathioprine treatment may lead to life-threatening reactions.

Keywords: Azathioprine; Azathioprine hypersensitivity syndrome; Drug reaction; Inflammatory bowel disease; Neutrophilic dermatosis; Sweet syndrome.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Clinical presentation: tender erythematous papules and plaques (a) with pustules and erosions (b) over the lower back and buttocks.
Fig. 2
Fig. 2
Histopathological features. a Lesion of acute folliculitis. Note the absence of the marked dermal edema and the hallmark diffuse neutrophilic dermal infiltration usually seen in classic Sweet syndrome. HE, original magnification ×50. b Dense neutrophilic infiltrate in the hair follicle. HE, original magnification ×200.
Fig. 3
Fig. 3
Tender erythematous plaques over the lower limbs.

References

    1. Cyrus N, Stavert R, Mason AR, Ko CJ, Choi JN. Neutrophilic dermatosis after azathioprine exposure. JAMA Dermatol. 2013;149:592–597. - PubMed
    1. Bidinger JJ, Sky K, Battafarano DF, Henning JS. The cutaneous and systemic manifestations of azathioprine hypersensitivity syndrome. J Am Acad Dermatol. 2011;65:184–191. - PubMed
    1. Choonhakarn C, Chaowattanapanit S. Azathioprine-induced Sweet's syndrome and published work review. J Dermatol. 2013;40:267–271. - PubMed
    1. Grelle JL, Halloush RA, Khasawneh FA. Azathioprine-induced acute febrile neutrophilic dermatosis (Sweet's syndrome) BMJ Case Rep. 2013 DOI: 10.1136/bcr-2013-200405. - PMC - PubMed
    1. Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol. 2006;55:369–389. - PubMed

Publication types